2018 Slow For Advertising Enforcement – But Don’t Get Complacent
Executive Summary
US FDA issued only one warning letter directly related to medical device advertising or promotion in 2018. But that doesn’t necessarily mean the agency has eased up on the area, according to attorneys Seth Ray and Alan Minsk.
You may also be interested in...
How Should US FDA Navigate Thorny First Amendment Conundrums: Former Chief Counsels Offer Advice
Daniel Troy suggests FDA increase its investment in science of consumer understanding, while Richard Cooper recommends the "bully pulpit" approach to get industry's attention. A panel of former chief counsels stressed that the agency cannot continue to ignore First Amendment free speech issues.
Warning Letters And Close-Outs – September 2023
It was a quiet month for warning letters at the FDA last month, with the agency issuing no new warning letters and closing out only one.
Proposed Rule Would Apply FDA’s Diagnostic Rules To LDTs
A proposed rule from the US Food and Drug Administration would allow the agency to take on regulation of lab-developed tests by phasing out the previous approach of enforcement discretion